The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
NAT10‐mediated mRNA N4‐acetylcytidine modification promotes bladder cancer progression
Open accessAbstract
Background: Dysregulation of the epitranscriptome causes abnormal expression of oncogenes in the tumorigenic process. Previous studies have shown that NAT10 can regulate mRNA translation efficiency through RNA acetylation. However, the role of NAT10‐mediated acetylation modification in bladder cancer remains elusive. Methods: The clinical value of NAT10 was estimated according to NAT10 expression pattern based on TCGA data set and the tumor tissue array. Acetylated RNA immunoprecipitation sequencing was utilized to explore the role of NAT10 in mRNA ac4C modification. Translation efficiency and mRNA stability assay were applied to study the effect of NAT10‐deletion on target genes. The nude mouse model and genetically engineered mice were conducted to further verify the characteristics of NAT10 in promoting BLCA progression and regulating downstream targets. Results: NAT10 was essential for the proliferation, migration, invasion, survival and the stem‐cell‐like properties of bladder cancer cell lines. NAT10 was responsible for mRNA ac4C modification in BLCA cells, including BCL9L, SOX4 and AKT1. Deficient NAT10 in both xenograft and transgenic mouse models of bladder cancer reduced the tumor burden. Furthermore, acetylated RNA immunoprecipitation sequencing data and RNA immunoprecipitation qPCR results revealed that NAT10 is responsible for a set of ac4C mRNA modifications in bladder cancer cells. Inhibition of NAT10 led to a loss of ac4C peaks in these transcripts and represses the mRNA's stability and protein expression. Mechanistically, the ac4C reduction modification in specific regions of mRNAs resulting from NAT10 downregulation impaired the translation efficiency of BCL9L, SOX4 and AKT1 as well as the stability of BCL9L, SOX4. Conclusions: In summary, these findings provide new insights into the dynamic characteristics of mRNA's post‐transcriptional modification via NAT10‐dependent acetylation and predict a role for NAT10 as a therapeutic target in bladder cancer. Highlights: NAT10 is highly expressed in BLCA patients and its abnormal level predicts bladder cancer progression and low overall survival rate. NAT10 is necessary and sufficient for BLCA tumourigenic properties. NAT10 is responsible for ac4C modification of target transcripts, including BCL9L, SOX4 and AKT1. NAT10 may serve as an effective and novel therapeutic target for BLCA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
N6-methyladenosine Modulates Messenger RNA Translation Efficiency
Wang, X., Zhao, B. S., Roundtree, I. A., Lu, Z., Han, D., Ma, H., Weng, X., Chen, K., Shi, H., & He, C. (2015) · Cell · doi:10.1016/j.cell.2015.05.014 · Cited by 3,483
Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation
Huang, H., Weng, H., Sun, W., Qin, X., Shi, H., Wu, H., Zhao, B. S., Mesquita, A., Liu, C., Yuan, C. L., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0045-z · Cited by 2,997
Self-citationLenis, A. T., Lec, P. M., Chamie, K., & MSHS, M. (2020) · JAMA · doi:10.1001/jama.2020.17598 · Cited by 2,051
The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells
Lin, S., Choe, J., Du, P., Triboulet, R., & Gregory, R. I. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.03.021 · Cited by 1,531
Cai, L., Sutter, B. M., Li, B., & Tu, B. P. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.05.004 · Cited by 701
Slobodin, B., Han, R., Calderone, V., Vrielink, J. A. F. O., Loayza-Puch, F., Elkon, R., & Agami, R. (2017) · Cell · doi:10.1016/j.cell.2017.03.031 · Cited by 434
Chemical inhibition of NAT10 corrects defects of laminopathic cells
Larrieu, D., Britton, S., Demir, M., Rodriguez, R., & Jackson, S. P. (2014) · Science · doi:10.1126/science.1252651 · Cited by 431
Cited by
FSP1: a key regulator of ferroptosis
Li, W., Liang, L., Liu, S., Yi, H., & Zhou, Y. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.05.013 · Cited by 287
Metadata
- Authors
- Wang, G., Zhang, M., Zhang, Y., Xie, Y., Zou, J., Zhong, J., Zheng, Z., Zhou, X., Zheng, Y., Chen, B., & Liu, C.
- Venue
- Clinical and Translational Medicine
- Publisher
- Wiley
- Published
- 2022-05
- Volume
- 12
- Issue
- 5
- Pages
- e738-e738
- ISSN
- 2001-1326 (ISSN-L)
- OpenAlex
- W4229070583
- Cited by
- 160
- References
- 8
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NAT10‐mediated mRNA N4‐acetylcytidine modification promotes bladder cancer progression. https://app.cochat.ai/papers/10.1002/ctm2.738
- The paper
- Wang, G., Zhang, M., Zhang, Y., Xie, Y., Zou, J., Zhong, J., Zheng, Z., Zhou, X., Zheng, Y., Chen, B., & Liu, C. (2022). NAT10‐mediated mRNA N4‐acetylcytidine modification promotes bladder cancer progression. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.738
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.